Laureate Pharma Announces Agreement with Enobia Pharma, Inc.

Laureate To Manufacture Enobia's Product Candidate ALP

Princeton, NJ, USA | July 31, 2007|  Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Enobia Pharma, a biotechnology company actively engaged in the development of enzyme replacement therapy for the treatment of hypophosphatasia. According to the agreement Laureate will produce Enobia Pharma's fusion protein for treatment of hypophosphatasia, a rare, and sometimes fatal metabolic bone disease characterized by skeletal hypomineralization. Terms of the manufacturing agreement were not disclosed.

"We are delighted by the confidence Enobia has shown by continuing to utilize our specialized experience in the manufacture of fusion proteins," said Robert J. Broeze, President & CEO of Laureate. "We have a successful relationship with Enobia and will work with them closely to help them achieve their manufacturing objectives."

"Our partnership with Laureate is an important component of our manufacturing strategy. We look forward to our partnership with Laureate and advancing our hypophosphatasia program into the clinic," said Robert Heft, President and CEO of Enobia.

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE), which builds value in high-growth, revenue stage information technology and life sciences businesses ( For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or This email address is being protected from spambots. You need JavaScript enabled to view it. or visit

About Enobia Pharma, Inc

Enobia Pharma is a privately held Canadian biotech company founded in 1997. The Company is engaged primarily in the discovery and clinical development of therapeutics to treat bone diseases where no drug therapy exists. Enobia anticipates initiating clinical studies in its lead program, enzyme-replacement therapy for hypophosphatasia, in the summer of 2008. The head office of Enobia is located at 2901 Rachel Street East, Suite 23, in Montreal, Quebec, CANADA. For more information on the company please contact Mr. Luc Cournoyer at 514-596-2901.


La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up